抗EGFR单抗类靶向药物在头颈部鳞癌综合治疗中的应用

王孝深; 胡超苏

doi:10.19401/j.cnki.1007-3639.2018.12.001

您当前的位置：

首页 >

文章列表页 >

抗EGFR单抗类靶向药物在头颈部鳞癌综合治疗中的应用

更新时间：2026-01-27

- 抗EGFR单抗类靶向药物在头颈部鳞癌综合治疗中的应用
- Anti-EGFR monoclonal antibodies combined with other modalities in treatment of head and neck squamous cell carcinoma
- 中国癌症杂志 2018年28卷第12期页码：881-887
- 作者机构：
  
  复旦大学附属肿瘤医院放疗中心, 复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2018.12.001
  中图分类号：
- 网络出版：2019-01-11，
  
  纸质出版：2019-01-11
- 稿件说明：
移动端阅览
王孝深,胡超苏. 抗EGFR单抗类靶向药物在头颈部鳞癌综合治疗中的应用[J]. 中国癌症杂志, 2018, 28(12): 881-887.

WANG Xiaoshen, HU Chaosu. Anti-EGFR monoclonal antibodies combined with other modalities in treatment of head and neck squamous cell carcinoma[J]. China Oncology, 2018, 28(12): 881-887.
王孝深,胡超苏. 抗EGFR单抗类靶向药物在头颈部鳞癌综合治疗中的应用[J]. 中国癌症杂志, 2018, 28(12): 881-887. DOI： 10.19401/j.cnki.1007-3639.2018.12.001.

WANG Xiaoshen, HU Chaosu. Anti-EGFR monoclonal antibodies combined with other modalities in treatment of head and neck squamous cell carcinoma[J]. China Oncology, 2018, 28(12): 881-887. DOI： 10.19401/j.cnki.1007-3639.2018.12.001.

摘要

头颈部肿瘤是世界上第6大常见的肿瘤。超过70%的头颈部肿瘤患者在首次确诊时即为局部晚期。尽管不断地努力改进治疗方法，但晚期病例的死亡率仍然居高不下。为了提高疗效，患者通常接受化疗、手术、放射治疗和分子靶向药物综合治疗。大量研究证实，表皮生长因子受体（epidermal growth factor receptor，EGFR）与肿瘤细胞的增殖和转移密切相关，EGFR在大多数头颈部肿瘤中高表达，对这些患者的预后有显著影响。抗EGFR单克隆抗体已经在一些国家被批准用于治疗局部晚期头颈鳞状细胞癌（head and neck squamous cell carcinoma，HNSCC）。本文综述了西妥昔单抗和尼妥珠单抗治疗HNSCC的研究进展。HNSCC的单克隆抗体靶向治疗，是选择西妥昔单抗还是尼妥珠单抗？本综述将围绕这一临床医生尤为关心的问题展开讨论。

Abstract

Head and neck cancer is the sixth most common cancer worldwide. More than 70% of the patients with head and neck carcinoma present with locally advanced disease when initially confirmed. Despite intense efforts to improve different treatment modalities

mortality rates in advanced cases remain high. In order to improve the outcome

patients usually receive combined treatment with chemotherapy

surgery

radiotherapy and molecular targeted drugs. Lots of studies have confirmed that epidermal growth factor receptor (EGFR) is closely related to the proliferation and metastasis of tumor cells

and EGFR is overexpressed in most head and neck cancer

which significantly affects the prognosis of those patients. Anti-EGFR monoclonal antibodies have been approved for the treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) in several countries. Here

we reviewed the scientific advances in HNSCC treated with cetuximab and nimotuzumab. Which one is better for treating the patients with HNSCC? Cetuximab or nimotuzumab? You will get some ideas from this review.

关键词

Keywords

references

浏览量

4082

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

端粒酶抑制剂BIBR1532联合自噬抑制剂CQ抑制黑色素瘤细胞生存的机制研究

奥希替尼治疗T790M突变的肺腺癌后小细胞转化1例